Retrospective real-life efficacy assessment of teneligliptin in Indian T2DM patients

Abstract

Background: Teneligliptin is been introduced recently in Indian market and data available are limited on Indian patients. Hence, the hospital based real life retrospective evaluation was planned out to evaluate, the efficacy of teneligliptin in type 2 diabetes mellitus in Indian population. Hence study was designed, a retrospective evaluation, of efficacy of teneligliptin in type 2 diabetes mellitus in Indian population.Methods: Data of 775 patients, who were prescribed teneligliptin was collected from hospital records. Teneligliptin 20mg was prescribed to all patients who were uncontrolled on other OHAs and for a mean duration of 8 weeks. Parameter evaluated in this study were change in FBG, PPBG and HbA1c from the baseline at 8week. With profile of outcome i.e. response and failure rates were also assessed with respect to age, gender, BMI and duration of diabetes.Results: Of 775 patients were enrolled, 427 were males and 348 females. The average age was 53.04 years among the study population. The mean duration of diabetes was 23 months. There was significant change in HbA1c, fasting and postprandial blood glucose levels at 8 week of teneligliptin therapy. Changes in HbA1c, FPG and PPG from baseline to end of study were-1.22±1.12% (p=0.001), -35.8±25.5mg/dl (p=0.001) and -60.7±28.6mg/dl (p=0.001) respectively. Out of 775 patients, 106 (13,7%) were non-responders where it was further sub analysed with different parameter such as age, gender, BMI and duration of diabetes in order to observe response of teneligliptin in diabetic patients.Conclusions: This real life retrospective evaluation showed efficacy of teneligliptin in real world scenario. It can be an effective alternative to conventional gliptins available for prescription in India.

Teneligliptin Real-World Effectiveness Assessment in Patients with Type 2 Diabetes Mellitus in India: A Retrospective Analysis (TREAT-INDIA 2)

“…The findings of these above two large-scale RWE studies in the Indian population reflect the effectiveness of teneligliptin. Similar findings were reported in another real-world efficacy study conducted in India by Nashikkar et al [14]. Changes in HbA1c, FPG and PPG from baseline to end of the study (after 8 weeks of teneligliptin therapy) were -1.22 ± 1.12% or -13.3 ± 12.2 mmol/mol (p = 0.001), -35.8 ± 25.5 mg/dL or -1.99 ± 1.42 mmol/L (p = 0.001) and -60.7 ± 28.6 mg/dL or -3.37 ± 1.59 mmol/L (p = 0.001), respectively.…”

A Real-World Observational Study on Diabetes Mellitus Patients Administering Dual Combination Therapy of Teneligliptin and Metformin to Evaluate Renal Function

“…The effectiveness of teneligliptin in the Indian population was first highlighted in the RWE study TREAT-INDIA (n = 4305) conducted by Ghosh et al, in which teneligliptin as a monotherapy and add-on therapy was shown to significantly reduce HbA1c (overall reduction by 1.37 ± 1.15%), FPG (overall reduction by 51.29 ± 35.41mg/dl) and PPG (overall reduction by 80.89 ± 54.27mg/dl). [12] Similar findings in the Indian population were reported by another real-world efficacy study conducted by Nashikkar et al [13].…”